Macrolide therapy of chronic rhinosinusitis

Rhinology

Volumn 45, Issue 4, 2007, Pages 259-267

  Cervin, Anders ^a,c   Wallwork, Ben ^b  

^a LUND UNIVERSITY   (Sweden)

^b GRIFFITH UNIVERSITY   (Australia)

^c HELSINGBORG HOSPITAL   (Sweden)

Author keywords

Chronic rhinosinusitis; Clarithromycin; Erythromycin; Inflammation; Macrolide; Roxithromycin

Indexed keywords

ANTIINFECTIVE AGENT; CLARITHROMYCIN; ERYTHROMYCIN; MACROLIDE; ROXITHROMYCIN;

BIOFILM; CHRONIC DISEASE; HUMAN; NEUTROPHIL CHEMOTAXIS; PATHOPHYSIOLOGY; REVIEW; RHINITIS; SINUSITIS;

ANTI-BACTERIAL AGENTS; BIOFILMS; CHEMOTAXIS, LEUKOCYTE; CHRONIC DISEASE; CLARITHROMYCIN; ERYTHROMYCIN; HUMANS; MACROLIDES; RHINITIS; ROXITHROMYCIN; SINUSITIS;

EID: 36749081617     PISSN: 03000729     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. McGuire JM, Bunch R, Anderson RC, Boaz HE, Flynn EH, Powell HM, et al. "Ilotycin" an new antibiotic. Antibiot Chemother. 1952; 2: 281-283.
2. Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med. 1998; 157: 1829-1832.
3. Kudoh S, Kimura H, Uetake T, et al. Clinical effect of low-dose, long-term macrolide antibiotic chemotherapy on diffuse panbronchiolitis. Jpn J Thorac Dis. 1984; 22: 254-254.
4. Kikuchi S, Susaki H, Aoki A, Ito O, Nomura Y. Clinical effect of long-term low-dose erythromycin therapy for chronic sinusitis (In Japanese with English abstract). Pract Otlo (Kyoto). 1991; 84: 41-47.
5. Georgitis JW, Matthews BL, Stone B. Chronic sinusitis: characterization of cellular influx and inflammatory mediators in sinus lavage fluid. Int Arch Allergy Immunol. 1995; 106: 416-421.
6. Suzuki H, Takahashi Y, Wataya H, Ikeda K, Nakabayashi S, Shimomura A, et al. Mechanism of neutrophil recruitment induced by IL-8 in chronic sinusitis. J Allergy Clin Immunol. 1996; 98: 659-670.
7. Bachert C, Wagenmann M, Rudack C, Hopken K, Hillebrandt M, Wang D, et al. The role of cytokines in infectious sinusitis and nasal polyposis. Allergy. 1998; 53: 2-13.
8. Demoly P, Crampette L, Mondain M, Enander I, Jones I, Bousquet J. Myeloperoxidase and interleukin-8 levels in chronic sinusitis. Clin Exp Allergy. 1997; 27: 672-675.
9. Wallwork B, Coman W, Feron F, Mackay-Sim A, Cervin A. Clarithromycin and prednisolone inhibit cytokine production in chronic rhinosinusitis. Laryngoscope. 2002; 112: 1827-1830.
10. Suzuki H, Asada Y, Ikeda K, Furukawa M, Oshima T, Takasaka T. Inhibitory effect of erythromycin on interleukin-8 secretion from exudative cells in the nasal discharge of patients with chronic sinusitis. Laryngoscope. 1999; 109: 407-410.
11. Wallwork B, Coman W, Mackay-Sim A, Cervin A. Effect of clarithromycin on nuclear factor-kappa B and transforming growth factor-beta in chronic rhinosinusitis. Laryngoscope. 2004; 114: 286-290.
12. Labro MT. Cellular and molecular effects of macrolides, on leukocyte function. Current pharmaceutical design. 2004; 10: 3067-3080.
13. Baeuerle P, Henkel, T. Function and activation of NF-kappaB in the immune system. Annu Rev Immunol. 1994; 12: 141-179.
14. Miyanohara T, Ushikai M, Matsune S, Ueno K, Katahira S, Kurono Y. Effects of clarithromycin on cultured human nasal epithelial cells and fibroblasts. Laryngoscope. 2000; 110: 126-131.
15. Desaki M, Takizawa H, Ohtoshi T, Kasama T, Kobayashi K, Sunazuka T, Omura S, Yamamoto K, Ito K. Erythromycin supresses nuclear factor kappa-B and activator protein-1 activation in human bronchial epithelial cells. Biochem Biophys Res Commun. 2000; 267: 124-128.
16. Stein G, Havlicheck, DH. The new macrolide antibiotics: Azithromycin and clarithromycin. Postgraduate medicine. 1992; 92: 269-282.
17. Bermudez L, Inderlied C, Young LS. Stimulation with cytokines enhances penetration of azithromycin into human macrophages. Antimicrob Agents Chemother. 1991; 35: 2625-2629.
18. Inamura K, Ohta N, Fukase S, Kasajima N, Aoyagi M. The effect of erythromycin on human peripheral neutrophil apoptosis. Rhinology. 2000; 38: 124-129.
19. Aoshiba K, Nagai A, Konno K. Erythromycin shortens neutrophil survival by accelerating apoptosis. Antimicrob Agents Chemother. 1995; 39: 872-877.
20. Hand W, Hand D, King-Thompson N. Antibiotic inhibition of the respiratory burst response in human polymorphonuclear leukocytes. Antimicrob Agents Chemother. 1990; 34: 863-870.
21. Braga P, Maci S, Dal Sasso M, Fonti E, Ghessi A. Effects of rokitamycin on phagocytosis and release of oxidant radicals of human polymorphonuclear leukocytes. Chemotherapy. 1997; 43: 190-197.
22. Lin H, Wang C, Liu C, Yu C, Kuo H. Erythromycin inhibits beta2-integrins (CD11b/CD18) expression, interleukin-8 release and intracellular oxidative metabolism in neutrophils. Respir Med. 2000; 94: 654-660.
23. Matsuoka N, Eguchi K, Kawakami A, Tsuboi M, Kawabe Y, Aoyagi T, Nagataki S. Inhibitory effect of clarithromycin on costimulatory molecule expression and cytokine production by synovial fibroblast-like cells. Clin Exp Immunol. 1996; 104: 501-508.
24. Stein GE, Havlichek DH. The new macrolide antibiotics. Azithromycin and clarithromycin. Postgrad Med. 1992; 92: 269-282.
25. Hirakata Y, Kaku M, Mizukane R, et al. Potential effects of erythromycin on host defense systems and virulence of Pseudomonas aeruginosa. Antimicrobial agents and chemotherapy. 1992; 36: 1922-1927.
26. Sofer D, Gilboa-Garber N, Belz A, Garber NC. 'Subinhibitory' erythromycin represses production of Pseudomonas aeruginosa lectins, autoinducer and virulence factors. Chemotherapy. 1999; 45: 335-341.
27. Yasuda Y, Kasahara K, Mizuno F, Nishi K, Mikasa K, Kita E. Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model. Antimicrobial agents and chemotherapy. 2007; 51: 1741-1752.
28. Wozniak DJ, Keyser R. Effects of subinhibitory concentrations of macrolide antibiotics on Pseudomonas aeruginosa. Chest. 2004; 125: 62S-69S; quiz 9S.
29. Takeoka K, Ichimiya T, Yamasaki T, Nasu M. The in vitro effect of macrolides on the interaction of human polymorphonuclear leukocytes with Pseudomonas aeruginosa in biofilm. Chemotherapy. 1998; 44: 190-197.
30. Nalca Y, Jansch L, Bredenbruch F, Geffers R, Buer J, Haussler S. Quorum-sensing antagonistic activities of azithromycin in Pseudomonas aeruginosa PAO1: a global approach. Antimicrob Agents Chemother. 2006; 50: 1680-1688.
31. Nakano T, Ohashi Y, Tanaka A, Kakinoki Y, Washio Y, Nakai Y. Roxithromycin reinforces epithelial defence function in rabbit trachea. Acta Otolaryngol. 1998; Suppl 538: 233-238.
32. Tamaoki J, Takeyama K, Yamawaki I, Kondo M, Konno K. Lipopolysaccharide-induced goblet cell hypersecretion in the guinea pig trachea: inhibition by macrotides. Am J Physiol. 1997; 272: 15-19.
33. Rhee C, Majima Y, Arima S, Jung H, Jinn T, Min Y, Sakakura Y. Effects of clarithromycin on rheological properties of nasal mucous in patients with chronic sinusitis. Ann Otol Rhinol Laryngol. 2000; 109: 484-487.
34. Rubin B, Druce H, Ramirez OE, Palmer R. Effect of clarithromycin on nasal mucous properties in healthy subjects and in patients with purulent rhinitis. Am J Respir Crit Care Med. 1997; 155: 2018-2023.
35. Nishi K, Mizuguchi M, Tachibana H, et al. Effect of clarithromycin on symptoms and mucociliary transport in patients with sino-bronchial syndrome. Nippon Shikkan Gakkai Zasshi. 1995; 33: 1392-1400.
36. Fecik RA, Nguyen PL, Venkatraman L. Approaches to the synthesis of immunolides: selective immunomodulatory macrolides for cystic fibrosis. Current Opin Drug Disc Dev. 2005; 8: 741-747.
37. Wallwork B, Coman W, Mackay-Sim A, Greiff L, Cervin A. A double-blind, randomized, placebo-controlled trial of macrolide in the treatment of chronic rhinosinusitis. Laryngoscope. 2006; 116: 189-193.
38. Pukhalsky AL, Shmarina GV, Kapranov NI, Kokarovtseva SN, Pukhalskaya D, Kashirskaja NJ. Anti-inflammatory and immunomodulating effects of clarithromycin in patients with cystic fibrosis lung disease. Mediators Inflamm. 2004; 13: 111-117.
39. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet. 2002; 360: 978-984.
40. Saiman L, Mayer-Hamblett N, Campbell P, Marshall BC. Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. Am J Respir Crit Care Med. 2005; 172: 1008-1012.
41. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2003; 290: 1749-1756.
42. Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax. 2002; 57: 212-216.
43. Black PN, Blasi F, Jenkins CR, et al. Trial of roxithromycin in subjects with asthma and serological evidence of infection with Chlamydia pneumoniae. Am J Respir Crit Care Med. 2001; 164: 536-541.
44. Kostadima E, Tsiodras S, Alexopoulos EI, et al. Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma. Eur Respir J. 2004; 23: 714-717.
45. Kraft M, Cassell GH, Pak J, Martin RJ. Myroplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin. Chest. 2002; 121: 1782-1788.
46. Banerjee D, Khair OA, Honeybourne D. The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD. Respir Med. 2005; 99: 208-215.
47. Banerjee D, Honeybourne D, Khair OA. The effect of oral clarithromycin on bronchial airway inflammation in moderate-to-severe stable COPD: a randomized controlled trial. Treat Respir Med. 2004; 3: 59-65.
48. MacLeod CM, Hamid QA, Cameron L, Tremblay C, Brisco W. Anti-inflammatory activity of clarithromycin in adults with chronically inflamed sinus mucosa. Adv Ther. 2001; 18: 75-82.
49. Suzuki H, Shimomura A, Ikeda K, Oshima T, Takasaka T. Effects of long-term low-dose macrolide administration on neutrophil recruitment and IL-8 in the nasal discharge of chronic sinusitis patients. Tohoku J Exp Med. 1997; 182: 115-124.
50. Yamada T, Fujieda S, Mori S, Yamamoto H, Saito H. Macrolide treatment decreased the size of nasal polyps and IL-8 levels in nasal lavage. Am J Rhinol. 2000; 14: 143-148.
51. Rubin BK, Druce H, Ramirez OE, Palmer R. Effect of clarithromycin on nasal mucus properties in healthy subjects and in patients with purulent rhinitis. Am J Respir Crit Care Med. 1997; 155: 2018-2023.
52. Rhee CS, Majima Y, Arima. S, Jung HW, Jinn TH, Min YG, et al. Effects of clarithromycin on rheological properties of nasal mucus in patients with chronic sinusitis. Ann Otol Rhinol Laryngol. 2000; 109: 484-487.
53. Ichimura K, Shimazaki Y, Ishibashi T, Higo R. Effect of new macrolide roxithromycin upon nasal polyps associated with chronic sinusitis. Auris Nasus Larynx. 1996; 23: 48-56.
54. Hashiba M, Baba S. Efficacy of long-term administration of clarithromycin in the treatment of intractable chronic sinusitis. Acta Otolaryngol Suppl (Stockh). 1996; 525: 73-78.
55. Cervin A, Kalm O, Sandkull P, Lindberg S. One-year low-dose erythromycin treatment of persistent chronic sinusitis after sinus surgery: clinical outcome and effects on mucociliary parameters and nasal nitric oxide. Otolaryngol Head Neck Surg. 2002; 126: 481-489.
56. Ragab SM, Lund VJ, Scadding G. Evaluation of the medical and surgical treatment of chronic rhinosinusitis: a prospective, randomised, controlled trial. Laryngoscope. 2004; 114: 923-930.
57. Moriyama H, Yanagi K, Ohtori N, Fukami M. Evaluation of endoscopic sinus surgery for chronic sinusitis: post-operative erythromycin therapy. Rhinology. 1995; 33: 166-170.
58. Fokkens W, Lund V, Mullol M. European Position Paper on Rhinosinusitis and Nasal polyps 2007. Rhinology. 2007; Suppi 20.
59. Suzuki H, Ikeda K, Honma R, Gotoh S, Oshima T, Furukawa M, et al. Prognostic factors of chronic rhinosinusitis under long-term low-dose macrolide therapy. ORL J Otorhinolaryngol Relat Spec. 2000; 62: 121-127.